ArticleObstetrics & gynecology science2026
First report of a combined hemostatic technique using Hydrofit® and SURGICEL Absorbable HemostatTM for intraoperative hemorrhage in gynecologic oncology surgery: a video article.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report the first use of Hydrofit® (Sanyo Chemical Industries, Kyoto, Japan), a polyurethane prepolymer sealant, combined with SURGICEL Absorbable Hemostat™ (Johnson & Johnson MedTech, Somerville, NJ, USA) as an oxidized cellulose carrier, for intraoperative hemorrhage control in gynecologic oncology surgery, with video documentation. Methods: Two patients undergoing open gynecologic oncology surgery developed hemorrhage refractory to conventional hemostatic measures. SURGICEL Absorbable Hemostat™ (Johnson & Johnson MedTech) coated with Hydrofit® (Sanyo Chemical Industries) was applied to the bleeding site with 3 minutes of manual compression. Surgical findings and postoperative courses were retrospectively reviewed. Institutional ethics approval and written informed consent were obtained from both patients. Result: Case 1: high-grade serous carcinoma of the fallopian tube with neuroendocrine features; total blood loss 4,439 g. Hemostasis at the resection surface was visually confirmed; the patient was discharged 7 days after surgery. At interval debulking surgery 4 months later, a fibrous mass adherent to the sigmoid colon with foreign body giant cells was noted at the application site; R0 resection was achieved. Case 2: cervical squamous cell carcinoma, International Federation of Gynecology and Obstetrics (2018) stage IIB; total blood loss 886 g. Hemorrhage from the right internal iliac vein was controlled within 3 minutes; the patient was discharged 11 days after surgery. Conclusion: This combined hemostatic technique may serve as an adjunctive option when conventional measures fail during gynecologic oncology surgery. The adhesion formation observed at reoperation warrants caution. Prospective evaluation using site-specific blood loss measurements is required to establish efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.